Board of Directors

As Chair and director of a number of healthcare and life sciences organisations including Owlstone Medical, ieso.ai, RNAvate and Our Future Health (Trading), Andrew remains closely connected to sector developments, ensuring the Board benefits from current industry insight. His role with the UKRI Medical Research Council further strengthens his perspective on emerging R&D trends. Andrew, with the support of the Company, maintains his skills, experience and his valuable international network through attendance at sector specific events and investor conferences and via external briefings and online training.

Andrew’s track record as both a founder of and investor in multiple life-science companies, and as a director of both private and public companies equips him with a practical understanding of risk, opportunity and value creation, which he brings to the Group’s decision-making.

Sarah brings extensive expertise in clinical and commercial pharmaceutical product development, manufacturing, supply, and licensing across diverse therapeutic areas. Her previous senior roles include Vice President of CMC and Technical Development at BTG Plc and Director of Outsourced Manufacturing at UCB-Celltech. She holds a BSc in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

She actively maintains her professional development through industry conferences, executive leadership programmes and research, ensuring she remains informed on emerging biopharma trends and governance best practices.

David has contributed significantly to Board discussions, using his background in both financial and operational matters to guide the cessation of the Tetris business and the delivery of the Royalty Financing Agreement.  He is a Chartered Accountant and completes the Continuing Professional Development requirements of the ICAEW.  This involves undertaking a significant amount of annual training, including on ethics and technical accounting matters.

Currently, he is Director of Research, Global Industries at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals. His role allows him to be close to all the key trends in the biotech sector, including financings and developments in the diabetes and metabolic diseases arena.

Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Sam has been ranked a top analyst by both the UK and Pan-European Extel surveys. He holds a degree from Cardiff University, and a Ph.D. in Pharmacology from the University of London.

During his time at Eli Lilly’s diabetes franchise (rising to VP International, Diabetes) Jeremy successfully launched several products. As COO of PHMR he led a team developing and implementing market access and pricing strategies.  In various Business Development roles he has been part of many teams on asset acquisition (both small molecule and company). Organisationally he has led an international organisation of 2,000 people and possesses seasoned experience of talent retention, development planning and compensation & benefits.

Jeremy has a BSc. in Applied Biology from Coventry University.

As an audit partner at PwC for over 15 years, he specialised in accounting and reporting matters for life sciences and technology companies, and this means that he is well-placed to offer constructive challenge on financial matters and to evaluate the work of the external auditors.  He is a Chartered Accountant and adheres to the Continuing Professional Development requirements of the ICAEW.  This involves undertaking a significant amount of annual training, including on ethics and financial reporting.  He also regularly attends biotechnology-specific events, to ensure that he keeps up to date with emerging sector trends and risks.